"Pharmaceutical Headline Jun" a number of new coronary therapy and vaccine trials suspended the "antidote" research and development of difficult steps.

(2020/10/14) Gao Gao exclusive Kailaiying 2.3 billion fixed increase "dream broken"! Still throwing $1 billion at the original idea; medical technology acquisitions top 5 from 2020; top 10 medical innovations in 2021: gene therapy, CD20 monoantials, PARP inhibitors, etc. (Click on the title, available in the original text) (Medicine 1st Time) Lilly COVID-19 antibody test has also been suspended domestic and foreign "new coronal antidote" research and development difficult days ago, the National Institutes of Health asked to suspend Lilly and AbCellera for COVID-19 hospitalized patients monoclonal antibody (LY-CoV555) treatment trial (ACTIV-3) recruitment of new patients.
, clinical trials of COVID-19 therapies and vaccines are still undergoing extensive shoulder review.
path to new crown vaccines for major pharmaceutical companies seems to be not going well.
: The research and development regulation of the "antidote" to new crown pneumonia should not be taken lightly.
"E drug manager" Gao Wei exclusive Kailaiying 2.3 billion fixed increase "dream broken"! Still throwing 1 billion not to change the original intention on the evening of October 12, Kailaiying issued a notice disclosing the non-public issue of shares issued in the report, non-public issue of new shares 101.787 million shares are expected to be listed on October 16, raising 2.311 billion yuan.
issued a total of nine issues, of which 4.4053 million shares were issued by Gao Gao Capital, with a allocation amounting to about $1 billion, which was still the largest buyer despite the failure to meet the wishes of the increase.
: The pace of deep-ploughed medical health seems far from over.
2021 Top 10 Medical Innovations: Gene Therapy, CD20 Monoantials, PARP Inhibitors, etc., cleveland Clinic in the United States recently named the "Top 10 Medical Innovations of 2021".
selected innovative technologies/therapies, including CD20 targeted therapy ocrelizumab, a new drug for cystic fibrosis, Trikafta, hepatitis C pangene therapy, PARP inhibitors and many other innovative drugs.
: These are innovative technologies that can improve treatment and change healthcare in the future.
: Medical Technology Mergers and Acquisitions TOP 5 Since 2020 According to PwC's Global Mergers and Acquisitions Industry Insights: Pharmaceuticals and Life Sciences report, in the first half of 2020, the number of transactions and transactions in the global pharmaceutical and life sciences industries have declined as a result of the new crown outbreak.
medical technology alone, data show that while more than $21 billion worth of mergers and acquisitions are still under way in the first half of 2020, the total value of healthcare technology transactions completed in this area is less than $2 billion.
: All five big acquisitions occurred in the second half of 2020.
.